A Cure for Skin Cancer?
Drug drops death rate 30 percent.
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
A new drug cuts the risk of death from melanoma by 30 percent, according to a late-stage clinical trial of the Bristol-Myers Squibb medicine, ipilimumab. Melanoma is an aggressive skin cancer, which rapidly spreads to organs, and the survival time after it metastasizes is usually six to nine months. Few treatments exist. In the study of 676 patients, more than 20 percent of those who took ipilimumab were alive after two years, with some alive after four. The dose was a 90-minute infusion every three weeks, for a total of four doses. The drug helps the immune system’s T-cells fight the cancer.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation